Application of activin receptor-interacting protein 2 (ARIP2) gene to preparation of medicament

A technology of activin receptors and gene drugs, applied in the field of gene therapy drugs for liver diseases, can solve the problems of ineffective treatment of liver damage and achieve remarkable results

Inactive Publication Date: 2012-02-08
柳忠辉
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above studies are still in the experimental stage because they only partially improve liver fibrosis and have no obvious effect on the treatment of liver injury, and there is no relevant research that has entered the clinical treatment stage.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of activin receptor-interacting protein 2 (ARIP2) gene to preparation of medicament
  • Application of activin receptor-interacting protein 2 (ARIP2) gene to preparation of medicament
  • Application of activin receptor-interacting protein 2 (ARIP2) gene to preparation of medicament

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] 1. Plasmid construction

[0019] The genes encoding human and mouse ARIP2 proteins have been registered and published in Genbank, BM563433 and AY157057, and the amino acid sequences encoded by the genes can be found in Sequence N0.1 and Sequence N0.2.

[0020] According to the gene sequence encoding human ARIP2 and its homologous gene such as mouse ARIP2, RT-PCR amplifies the target gene fragment of ARIP2, and clones the target fragment into eukaryotic expression vectors such as pcDNA3, pCIneo and pCMV4, and recombinant adenovirus transfer plasmids and Backbone plasmids pShuttle-cmv and pAdEasy-1, etc., were transformed into competent Escherichia coli DH5α with the ligated products, positive colonies were picked and amplified, and plasmids were extracted by alkaline lysis. Use EcoRI and XhoI for double enzyme digestion and identification, and then analyze the DNA sequence of the recombinant expression plasmid with the correct fragment, and take the expression plasmid wi...

Embodiment 2

[0023] Example 2 Compatibility of Activin Receptor Interacting Protein 2 and Interferon

[0024] pcDNA3-ARIP2 5 μg

[0025] α-Interferon 10,000 units

experiment example 1

[0026] Experimental example 1 The relationship between ARIP2 gene expression and liver injury and liver fibrosis in the present invention is confirmed by animal experiments

[0027] Experimental animal model preparation

[0028] 1) Con A-induced acute liver injury model in mice: 48 male C57BL / 6 mice (body weight 20-22g) were taken for 7 days, and they were randomly divided into two groups, 24 in the Control group and 24 in the Con A group. Group 24, Con A group with 15mg Con A / kg body weight (1g / L normal saline solution) tail vein injection once, Control group with equal volume of normal saline buffer solution tail vein injection once. 1d, 3d, 5d and 7d after the injection, 6 mice were sacrificed by enucleation of eyeballs and bloodletting, and the serum was separated for determination of transaminases.

[0029] 2) Con A-induced chronic liver injury model in mice: 48 male C57BL / 6 mice (body weight 20-22g) were taken for 7 days, and they were randomly divided into two groups, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of an activin receptor-interacting protein 2 (ARIP2) gene to preparation of a medicament, relating to the field of liver disease gene therapy medicaments. The application of the ARIP2 gene as a gene therapy medicament for treating liver diseases is characterized in that: a eukaryotic cell expression vector of a recombinant ARIP2 gene is transfected with liver cells, and ARIP2 proteins expressed by the ARIP2 gene in the liver cells can be used for maintaining liver cell survival and reducing inflammatory mediators and extracellular matrixes, so that the regeneration of liver parenchyma cells is facilitated, and liver inflammation and fibration are suppressed. The ARIP2 gene can be used for treating acute liver diseases and chronic liver diseases, including liver diseases such as hepatofibrosis, hepatocirrhosis and the like.

Description

technical field [0001] The invention relates to the field of gene therapy drugs for liver diseases. It is found that the ARIP2 protein expressed by the activin receptor-interacting protein 2 (ARIP2) gene in liver cells can protect the liver from damage and resist liver fibrosis , the present invention uses recombinant ARIP2 gene injection to treat acute and chronic liver diseases, including liver fibrosis and liver cirrhosis. Background technique [0002] There are nearly 150 million hepatitis virus-infected patients in China, among whom there are more than 10 million patients with hepatitis, and the most important complication of various hepatitis is also the main cause of death of patients with hepatitis——chronic liver injury-induced liver fibrosis, further development of liver fibrosis Development leads to irreversible cirrhosis. With the in-depth research on the pathogenesis of liver cell injury and liver fibrosis, many cytokines and signal transduction networks are fou...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K38/21A61P1/16A61K38/18
Inventor 柳忠辉王轶楠
Owner 柳忠辉
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap